Harmony

About the offering

Harmony Baby Nutrition is a Natick, MA-based early-stage infant and toddler nutrition company developing baby formulas built around human milk-derived components. The company aims to bridge the nutritional and functional gap between conventional cow's milk-based formulas and human breast milk by using human milk oligosaccharides (HMOs), lactose as the primary carbohydrate, and human milk-inspired proteins and fatty acids assembled through deep formulation science. The company argues that most existing formulas rely on cow's milk proteins that the human immune and digestive systems were never designed to process, and that up to 1 in 5 babies cannot tolerate standard formulas, suffering inflammation and digestive distress during critical developmental months. Harmony's approach avoids stripping allergens from cow's milk (the conventional hypoallergenic route, which often results in poor taste and added sugars) and instead builds an entirely new formulation matrix modeled on human milk components. The company is led by founder and CEO Wendel Afonso, a serial entrepreneur with 20+ years in infant nutrition who previously founded INVITA Specialized Nutrition (ranked #2 fastest-growing SME in Brazil by Deloitte), holds 7 patents, and has authored 30 publications. The VP of Formulation, Mariana Souza, holds a PhD in Food Science and has launched 15+ clinical nutrition products. The team is advised by pediatric allergy and immunology experts from Harvard/Massachusetts General Hospital, UC Davis, Baylor College of Medicine, and the University of Rochester, as well as the former President of Gerber (a Nestlé subsidiary) and former Nestlé and Pfizer regulatory and manufacturing leaders. Harmony has raised $7.5M from institutional VCs including SOSV, Safar Partners, Rethink Food, and MassVentures, plus a $5.9M Brazilian government grant, totaling approximately $13.5M in combined funding and grants. The company has filed 4 patents and developed 55+ prototypes. Its first product, Melodi, is an allergy-friendly toddler formula (targeting ages 12 months and up) slated to launch in 2026. Melodi benefits from FDA clearance based on its use of already-approved ingredients and its toddler (not infant) positioning. Manufacturing is expected to begin in early 2026. The company plans to expand into infant formula (ages 0–12 months) following a clinical safety trial, and has a broader product pipeline including extensively hydrolyzed formulas, amino acid formulas, and eventually precision fermentation-based Gen 2 and Gen 3 products incorporating bioactive human milk proteins — with Gen 2 targeted for late 2029 and Gen 3 for 2030. Harmony's IP strategy centers on a family of composition-of-matter patents covering hypoallergenic formulas (Gen 1 and 2) and routine formulas (Gen 3), designed to protect specific combinations of human milk components (lactose, HMOs, human milk proteins) across ingredient ranges allowed by global regulators. The company has conducted a Freedom to Operate (FTO) analysis supported by a specialized IP attorney. The company differentiates itself from competitors such as Kepos (an adult-supplement-focused, precision fermentation synbiotic) and Prolacta Bioscience (which targets NICU/hospital premature infant nutrition using donor human milk) by operating in the consumer-facing, healthy full-term infant and toddler nutrition space. The target market is the $100B+ global pediatric formula market, with the hypoallergenic segment serving up to 17% of infants experiencing food protein-induced allergic symptoms. The company reports a retail price of approximately $50 per can and estimates a customer lifetime value of over $2,400. Revenue projections indicate $7M+ in sales from Gen 1 products by 2029, with significantly higher enterprise value anticipated as Gen 2 and Gen 3 products approach regulatory approval. The company points to historical M&A precedent in the infant nutrition space (Nestlé, Danone, Reckitt) as evidence of exit potential. The current Wefunder crowdfunding round has raised approximately $670,588 from 196+ investors, surpassing its initial goal, with a minimum investment of $250.

FAQ